Hemato-Linné

Faculty of Medicine | Lund University

Menu

Hemato-Linné

A joint initiative to understand blood generation in health and disease

  • Hemato-Linné is an excellence research environment in hematopoiesis at Lund University. 
  • Financed by the Swedish Research Council through a 10-year Linnaeus grant, Hemato-Linné was established in 2006 as a world-leading research environment to study the regulation of normal and leukemic hematopoietic stem cells and blood lineage development.
  • Hemato-Linné also focuses on excellence in research training and career development of young scientists.

 

News

The application period for the Preparatory Program in Stem Cell Biology 2016 is now open. The application deadlines for round 1 and round 2 are August 17th, 2015 and October 15th, 2015, respectively.

preparatory program 2016

In October 2014, two research teams centered around the Hemato-Linné members Mikael Sigvardsson and Stefan Karlsson were awarded a prestigious Knut and Alice Wallenberg grant each for research projects with high scientific potential. In an interview series, the Knut and Alice Wallenberg Foundation now reports about the aims, challenges, and future implications of the respective projects.

Stefan Karlsson

The Division of Molecular Medicine and Gene Therapy turns 20 years and we therefore take pleasure in announcing a symposium in honor of Stefan Karlsson. Stefan founded the Division in 1995 and has since then been the driving force in establishing the strong hematopoiesis environment at Lund University.  

Venue: Belfrage Lecture hall, BMC D15, Klinikgatan 32
Date and time: May 15th at 13.00 - 16.30

Welcome!

johan and kavitha
Photo: K. Branzén

Congratulations to HematoLinné PI Johan Flygare, who was awarded funding from The Diamond Blackfan Anemia Foundation (DBAF) and Diamond Blackfan Anemia Canada (DBAC) to continue his research on the development of safer and more potent drugs to treat DBA. Using a chemical screen of 12,000 substances, Dr. Flygare and his team have identified several potential drug targets that showed a therapeutic effect on the formation of red blood cells. They will now focus their efforts on the characterisation of these novel compounds and their therapeutic mechanisms.

Site overview